NU SKIN ENTERPRISES, INC. Debt Disclosure
| 7. |
Long-Term Debt
|
|
Facility or Arrangement
|
Original
Principal
Amount
|
Balance as of
December 31,
2024 (1)(2)
|
Balance as of
December 31,
2023 (1)(2)
|
Interest
Rate
|
Repayment
Terms
|
|||||
|
Credit Agreement term loan facility
|
$400.0 million
|
$360.0 million
|
$385.0 million
|
30 day: 6.71%
|
21% of the principal amount is in increasing quarterly installments over a five-year
period that began on September 30, 2022, with the remainder payable at the end of the five-year term.
|
|||||
|
Credit Agreement revolving credit facility
|
$35.0 million
|
$120.0 million
|
30 day: 6.71%
|
Revolving line of credit expires June 14, 2027.
|
| (1) |
As of December 31, 2024 and 2023, the current portion of the Company’s debt
(i.e. becoming due in the next 12 months) included $20.0 million and $25.0 million, respectively, of the balance of its term loan under the Credit Agreement and $10.0 and $0, respectively, of the balance under the revolving line of
credit.
|
| (2) |
The carrying value of the debt reflects the amounts stated in the above
table, less debt issuance costs of $1.4 million and $2.0 million as of December 31, 2024 and 2023, respectively, related to the Credit Agreement, which are not reflected in this table.
|
|
Year Ending December 31,
|
||||
|
2025
|
$
|
30,000
|
||
|
2026
|
20,000
|
|||
|
2027
|
345,000
|
|||
|
2028
|
—
|
|||
|
2029
|
—
|
|||
|
Thereafter
|
—
|
|||
|
Total (1)
|
$
|
395,000
|
||
| (1) |
The carrying value of the debt in the above table excludes debt issuance
costs of $1.4 million.
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Feb 14, 2025 | Showing above |
| 2023 | Feb 15, 2024 | |
| 2022 | Feb 16, 2023 | |
| 2021 | Feb 16, 2022 | |
| 2020 | Feb 11, 2021 | |
| 2019 | Feb 13, 2020 | |
| 2018 | Feb 14, 2019 | |
| 2017 | Feb 16, 2018 | |
| 2016 | Feb 27, 2017 | |
| 2015 | Feb 18, 2016 | |
About Debt Disclosures
Debt disclosures detail a company's borrowing structure — the types of instruments, interest rates, maturity schedule, and covenant restrictions that define its financial obligations and flexibility. This section is essential for assessing refinancing risk, interest rate exposure, and the margin of safety against financial distress.
Key signals: the maturity schedule reveals concentration risk — large maturities within 1-2 years during tight credit markets can force dilutive refinancing or asset sales. Compare the fair value of debt against carrying amount to gauge whether the market views the company's credit risk differently than the balance sheet suggests. Watch covenant compliance disclosures for tightening cushions, especially leverage and interest coverage ratios. Variable-rate debt exposure quantifies sensitivity to interest rate changes. Secured versus unsecured mix affects recovery rates and future borrowing capacity. Compare net debt-to-EBITDA against industry peers and covenant limits to assess financial health.